Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-L03 fixed-dose combination vs co-administration in healthy volunteers
NCT07158346Phase 1Completed
- Sponsor
- Celltrion
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CT-L03 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration at 96 hours and Maximum Plasma Concentration at 96 hours. Started Aug 2025; status: completed.
02
Drugs
CT-L03
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07158346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158346.